Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids. The company lead product comprises Vascepa, a prescription-only omega-3 fatty acid comprising icosapent ethyl as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It also engages in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc.
Amarin Corporation plc was founded in 1989 and is headquartered in Dublin, Ireland.
Address
2 Pembroke House Upper Pembroke Street 28-32, Dublin 2
DUBLIN, CT 06355
Ireland
+353-1-6699020 (Phone)
+1-860-5724940 (Fax)
DUBLIN, CT 06355
Ireland
+353-1-6699020 (Phone)
+1-860-5724940 (Fax)
Website
http://www.amarincorp.comKey stats and ratios
| Q3 (Sep '13) | 2012 | |
| Net profit margin | -581.74% | - |
| Operating margin | -480.47% | - |
| EBITD margin | - | - |
| Return on average assets | -77.12% | -81.96% |
| Return on average equity | - | - |
| Employees | 111 |
No comments:
Post a Comment